Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 4/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7684920 | 0.88 | AR (0.42) | ARPGRBCHEDRD2DRD4 | |
| SCHEMBL6648117 | 0.88 | AR (0.42) | ARPGRBCHEDRD2DRD4 | |
| SCHEMBL6650735 | 0.82 | AR (0.44) | ARPGRBCHE | |
| SCHEMBL6649457 | 0.79 | AR (0.43) | ARPGRBCHENQO2MTNR1A | |
| SCHEMBL14975544 | 0.79 | MEN1 (0.39) | ARPGRDRD2DRD4ESR1 | |
| SCHEMBL20570921 | 0.78 | BCHE (0.57) | ARPGRBCHE | |
| SCHEMBL8140136 | 0.76 | DRD2 (0.42) | ARPGRDRD2DRD4ESR2 | |
| SCHEMBL19909810 | 0.70 | DRD2 (0.40) | ARDRD2DRD4ESR2CYP19A1 | |
| SCHEMBL28557924 | 0.70 | DRD2 (0.40) | DRD2DRD4ESR2 | |
| SCHEMBL29519369 | 0.70 | DRD2 (0.40) | DRD2DRD4ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2004-09-23 | — | — | US | disclosed |
| US-6696459-B1 | USING HIGH AFFINITY, HIGH SELECTIVITY QUINOLINE DERIVATIVESW | LIGAND PHARMACEUTICALS INC. | 2004-02-24 | — | — | US | disclosed |
| EP-1382597-A2 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-0800519-B1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-6448405-B1 | COUPLING A 2-HALO-5-NITROBENZOIC ACID AND A 2-METHOXYPHENYL BORONIC ACID; CYCLIZING TO A NITROBENZOCOUMARIN; REDUCING TO THE AMINE; CONVERTING TO A COUMARINO(3,4-F)QUINOLINE; REDUCTION TO A 5H-CHROMENO(3,4-F)QUINOLINE | LIGAND PHARMACEUTICALS INCORPORATED | 2002-09-10 | — | — | US | disclosed |
| EP-1043326-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1043325-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1043315-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1041071-A1 | Methods for the preparation of coumarine derivatives | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-1041066-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-04 | — | — | EP | disclosed |
| US-5994544-A | PRODUCING A 5H-CHROMENO(3,4-F)QUINOLINE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-11-30 | — | — | US | disclosed |
| US-5696127-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696130-A | Tricyclic steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696133-A | ADMINISTERING COMPOUND WHICH MODULATES ACTIVITY OF PROGESTERONE RECEPTOR | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693646-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | NR5A1, ESRRA, NR3C2 | AR 7/4885PGR 29/4885SHBG 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.